Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 26 September 2019

Indication(s)

CINQAERO is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Moderate to severe asthma

Moderate to severe asthma

Access the comprehensive Learning Zone for moderate to severe asthma. Containing details about pathophysiology, a complete overview of asthma and daily reports from ERS Congress 2019. 

Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic interstitial lung disease that occurs mostly in older adults, is limited to the lungs and often displays a characteristic imaging and histological appearance. Find out how to diagnose IPF and the latest interventions available for patients living with this burden.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/003912
Orphan designation No
Date First Approved 16-08-2016
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Teva B.V.